Quest Diagnostics insider plans sale of 55K DGX shares (Form 144)

Quest Diagnostics (DGX) has a Form 144 filing indicating a planned sale of 55,093 shares of its common stock through Fidelity Brokerage Services LLC on the NYSE.

Rhea-AI Filing Summary

Quest Diagnostics (DGX) has a Form 144 filing indicating a planned sale of 55,093 shares of its common stock through Fidelity Brokerage Services LLC on the NYSE. The shares have an aggregate market value of $10,589,761.55 based on the data in the notice.

The filing states that 111,242,362 common shares are outstanding. The seller acquired the 55,093 shares as common stock on 11/25/2025, originating from an option granted on 02/21/2017 and paid for in cash.

FAQ

What does the Quest Diagnostics (DGX) Form 144 filing disclose?

The Form 144 for Quest Diagnostics (DGX) discloses an intended sale of 55,093 shares of common stock, with an aggregate market value of $10,589,761.55, on the NYSE through Fidelity Brokerage Services LLC.

How many Quest Diagnostics (DGX) shares are covered by this Form 144?

The notice covers 55,093 shares of Quest Diagnostics common stock to be sold.

What is the reported market value of the Quest Diagnostics (DGX) shares to be sold?

The aggregate market value of the Quest Diagnostics shares listed in the Form 144 is $10,589,761.55.

On which exchange and through which broker are the DGX shares planned to be sold?

The Form 144 indicates the DGX common shares are to be sold on the NYSE through Fidelity Brokerage Services LLC.

How and when were the Quest Diagnostics (DGX) shares being sold acquired?

The 55,093 DGX common shares were acquired on 11/25/2025, originating from an option granted on 02/21/2017, with the payment described as cash.

How many Quest Diagnostics (DGX) common shares are outstanding according to the notice?

The Form 144 reports that 111,242,362 Quest Diagnostics common shares are outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/25/2025 - 04:24 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001599837
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	QUEST DIAGNOSTICS INC
SEC File Number	001-12215
Address of Issuer	500 PLAZA DRIVE SECAUCUS NEW JERSEY 07094
Phone	9735202700
Name of Person for Whose Account the Securities are To Be Sold	Davis J. E.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	55093	10589761.55	111242362	11/25/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/25/2025	Option Granted - 02/21/2017	Issuer			55093	11/25/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/25/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/26/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Gary Redman, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for James E. Davis
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)